BMC pregnancy and childbirth · 2025
Risk of intrauterine transmission and pregnancy outcomes following SARS-CoV-2 infection in the first or second trimester: a prospective cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Xiangyu, Jiang Zihan, Cao Peixuan, Wei Hongxia, Jiang Peipei, Yang Ying, Zhou Chunxiang, Hu Xiaohan, Wu Xing, Liu Wei, Gu Leilei, Zhang Yingwei, Xu Hongpan, Li Jie
Аннотация
BACKGROUND: China encountered a nation-wide outbreak of SARS-CoV-2 transmission during December 2022-January 2023 after discontinuation of the strict zero-Covid-19 policy on December 7, 2022. However, data on its impact on early pregnancy was limited. We aimed to investigate the risk of intrauterine transmission and pregnancy outcomes following SARS-CoV-2 infection during the first or second trimester, and to assess the safety of post-infection amniocentesis.
METHODS: From January 31 to February 28, 2023, we prospectively invited all pregnant women who were referred for amniocentesis to perform chromosomal microarray analysis to participate in this study. Based on the infection time, the participants were divided into group one with Covid-19 in the first trimester and and group two with Covid-19 in the second trimester. Amniotic fluid samples were analyzed for SARS-CoV-2 RNA using qRT-PCR. Pregnancy and neonatal outcomes were assessed through obstetric ultrasound examination and follow-ups.
RESULTS: In total, 225 women with 239 fetuses (14 sets of twin pregnancy) underwent amniocentesis in the study period. Finally, 134 pregnant women (6 sets of twin pregnancy) were included. They were infected with SARS-CoV-2 at gestational age 3 to 25 weeks. Amniocentesis was performed at gestational age 17 to 33 weeks. None of the 140 amniotic fluid samples tested positive for SARS-CoV-2 RNA, indicating no intrauterine transmission. Rates of premature delivery (8.8%) and birth weight (3335.8 g vs. 3279.9 g, p = 0.607) did not differ significantly between the first and second trimester infection groups.
CONCLUSION: No evidence of vertical transmission or adverse pregnancy outcomes was observed following SARS-CoV-2 infection during the first or second trimesters. Amniocentesis beyond the acute phase of infection appears safe.
METHODS: From January 31 to February 28, 2023, we prospectively invited all pregnant women who were referred for amniocentesis to perform chromosomal microarray analysis to participate in this study. Based on the infection time, the participants were divided into group one with Covid-19 in the first trimester and and group two with Covid-19 in the second trimester. Amniotic fluid samples were analyzed for SARS-CoV-2 RNA using qRT-PCR. Pregnancy and neonatal outcomes were assessed through obstetric ultrasound examination and follow-ups.
RESULTS: In total, 225 women with 239 fetuses (14 sets of twin pregnancy) underwent amniocentesis in the study period. Finally, 134 pregnant women (6 sets of twin pregnancy) were included. They were infected with SARS-CoV-2 at gestational age 3 to 25 weeks. Amniocentesis was performed at gestational age 17 to 33 weeks. None of the 140 amniotic fluid samples tested positive for SARS-CoV-2 RNA, indicating no intrauterine transmission. Rates of premature delivery (8.8%) and birth weight (3335.8 g vs. 3279.9 g, p = 0.607) did not differ significantly between the first and second trimester infection groups.
CONCLUSION: No evidence of vertical transmission or adverse pregnancy outcomes was observed following SARS-CoV-2 infection during the first or second trimesters. Amniocentesis beyond the acute phase of infection appears safe.